Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.75

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $16.75.

A number of equities analysts have commented on the stock. Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th.

Amicus Therapeutics Trading Up 2.1 %

Shares of FOLD traded up $0.16 during trading hours on Friday, reaching $7.68. 4,493,430 shares of the company traded hands, compared to its average volume of 2,645,063. The stock's fifty day moving average price is $8.05 and its 200 day moving average price is $9.35. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The firm has a market cap of $2.36 billion, a price-to-earnings ratio of -42.67, a PEG ratio of 1.51 and a beta of 0.79. Amicus Therapeutics has a 12-month low of $6.20 and a 12-month high of $12.65.

Institutional Trading of Amicus Therapeutics

Several hedge funds have recently modified their holdings of the company. Virtus Fund Advisers LLC bought a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $29,000. Covestor Ltd lifted its holdings in shares of Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 2,312 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Amicus Therapeutics in the 4th quarter worth $59,000. GAMMA Investing LLC grew its stake in shares of Amicus Therapeutics by 1,610.8% during the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 7,007 shares during the last quarter. Finally, R Squared Ltd purchased a new stake in Amicus Therapeutics during the 4th quarter worth approximately $79,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.